Topotecan for recurrent cervical cancer after platinum-based therapy

N. R. Abu-Rustum, S. Lee, L. S. Massad

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


The activity and toxicity of topotecan in women with recurrent cervical cancer are described from a case series of women with recurrent cervical cancer who had measurable disease and were not amenable to cure by surgery or radiation. All patients had prior platinum-based chemotherapy and developed progressive disease. Topotecan was given as 1 mg/m2/day over 30 min for 5 days every 3 weeks until progression of disease or prohibitive toxicity. Between July 1998 and July 1999, 12 patients received a total of 20 cycles of topotecan. Median age was 41 years (range 21-62), and 11 (92%) patients had prior whole pelvic radiation. The mean number of topotecan cycles was 1.5 (median 1, range 1-3). There were two partial responses (16.7%; 95% CI, 2% to 48%), both in prior radiation fields. Five patients required red blood cell transfusions, four had grade II nausea and vomiting, two developed sepsis (one with neutropenia), one developed fever, and one reported hyperpigmentation. There were no treatment-related mortalities. Although topotecan appears to exhibit modest activity in recurrent cervical cancer after radiation and platinum-based therapy, bone marrow toxicity may limit the utility of this regimen without hematopoietic growth factor support.

Original languageEnglish
Pages (from-to)285-288
Number of pages4
JournalInternational Journal of Gynecological Cancer
Issue number4
StatePublished - Sep 28 2000
Externally publishedYes


  • Cervical cancer
  • Chemotherapy
  • Topotecan
  • Toxicity

Fingerprint Dive into the research topics of 'Topotecan for recurrent cervical cancer after platinum-based therapy'. Together they form a unique fingerprint.

Cite this